Technology
Combining the power of multiple antibodies
in ONE MOLECULE
At Hinge Bio, we are targeting difficult-to-treat diseases by merging multiple, fully-active antibodies into a single molecule, while maintaining the full functionality of an individual antibody, as well as enhancing the targeting and immune effector functions.
Hinge Bio’s proprietary GEM-DIMER™ platform allows us to combine the power of multiple full antigen-binding fragments, not just single chain Fvs or single domains, into a single molecule with entirely new functionality for superior safety and efficacy.
THE GEM-DIMER™ PLATFORM
Antibodies designed by the GEM-DIMER™ platform enhance immune effector functions with a greater degree of multivalency and multispecificity than possible with conventional approaches producing molecules with entirely new functionality for superior safety and efficacy.
GEM-DIMER™ platform is [versatile, tunable, and efficient] for the desired target product profile and has demonstrated encouraging in vitro and in vivo proof-of-concept in multiple therapeutic programs.
Hinge Bio is at the forefront in the field of off-the-shelf multispecifics with more powerful activity to treat severe diseases with unmet needs.
HB2198
Resetting the immune system
Hinge Bio’s lead program HB2198 is designed to improve efficacy, safety, and convenience for the treatment of B cell-mediated autoimmune disorders, such as Systemic Lupus Erythematosus (SLE). HB2198 has demonstrated in vivo proof of concept to rapidly and deeply (>99%) deplete of B cells.
The therapeutic goal of HB2198 is to achieve a “reset” of the immune system through rapid and deep B cell depletion in both peripheral blood and lymphoid tissues, without the challenges and toxicities associated with CAR-T or T cell Engagers (TCEs).
B CELL DEPLETION
B lineage cells are a key part of the adaptive immune system and comprise cells of diverse maturation stages and functions. it is now clear that B lineage cells also play a key role in regulating other immune cells.
Depletion of B cells has resulted in major therapeutic benefits in autoimmune diseases and hematological malignancies. Nonetheless, there persists a notable unmet need in both autoimmune disease and oncology.